Changes of VEGF, HIF-1α, OPN and CTGF levels in serum of HCC patients after recombinant human endostatin combined with transcatheter arterial chemoembolization / 中国生化药物杂志

ABSTRACT

Objective To explore the effect of recombinant human endostatin combined with transcatheter arterial chemoembolization on vascular endothelial growth factor (VEGF), hypoxia inducible factor-1 alpha(HIF-1α), osteopontin (OPN) and connective tissue growth factor (CTGF) levels in serum of HCC patients.Methods 90 cases of primary liver cancer patients were randomly divided into control group and observation group, 45 cases in each group.The control group received the routine chemotherapy of hepatic artery embolization, and the observation group received recombinant human vascular endostatin combined with hepatic arterial chemoembolization.The serum levels of VEGF, HIF-1α, OPN, and CTGF were detected by enzyme-linked immunosorbent assay before treatment, 3 days and 5 days after operation, then the correlations were analyzed.Results The VEGF, HIF-1α, OPN, CTGF levels after 3 days and 5 days were higher than those before surgery in control group and observation group (P<0.05), the above indexes after 5 days were lower than those after 3 days in both groups (P<0.05), and VEGF, OPN and CTGF levels except for HIF-1αin observation group were significantly lower than those in control group after 5 days (P<0.05).There existed significant positive correlation between serum VEGF and HIF-1α, OPN, CTGF concentration levels(r=0.985, 0.995, 0.959,P<0.05) in 90 cases of liver cancer patients, highly positive correlation between HIF-1αand OPN, CTGF levels (r=0.842,0.874, P<0.05), and moderately positive correlation between OPN and CTGF concentrations (r=0.755,P<0.05).Conclusion The efficacy of recombinant human vascular endostatin combined with transcatheter arterial chemotherapy and embolization in the treatment of primary hepatocellular carcinoma is good.There exsits closely correlation of VEGF, HIF-1α, OPN and CTGF levels in serum, which could reflect clinical efficacy.